1. Medtech Insight
  2. >>Geography

MDR Flowchart Explains When Legacy Devices Can Benefit From Extended Timelines

 
• By Amanda Maxwell

Are you uncertain whether your medtech products can benefit from transition period extensions that feature in the March 2023 amending Regulation to the MDR? The latest European Commission document offers help.

Algorithm, flowchart. 3D rendering isolated on white background

The European Commission has published a document to help manufacturers and other relevant medtech sector actors decide whether a device can benefit from the extended transitional period brought in under the recent amending regulation to Medical Device Regulation and under what conditions. (Also see "MDR Amending Regulation Officially Published And Already In Force" - Medtech Insight, 20 March, 2023.)

The document is available here:

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Europe

More from Geography

A Year After Exiting The Ventilator Market, Medtronic Recalls Thousands Of Newport Devices

 
• By Brian Bossetta

After two serious injuries and one death linked to some of its ventilators, Medtronic has recalled the devices and asked customers to stop using them and find alternative means. The action comes more than a year after the company left the market.

‘UK Must Put Adoption On A Par With Innovation’

 
• By Ashley Yeo

Market access concerns dominated at the annual BioWales In London event, where AstraZeneca set out industry’s priorities and the UK Office for Life Sciences struck an optimistic tone about how the UK will lastingly improve uptake of innovation.

Sofinnova And NVIDIA Partner To ‘Supercharge’ Computation For European Startups

 
• By Natasha Barrow

European venture capital firm Sofinnova Partners’ portfolio companies BioCorteX, Bioptimus, Cure51 and Latent Labs will benefit from the investor’s new partnership with tech giant NVIDIA.